Menu
Back to Journals » Drug Design, Development and Therapy » Volume 13
Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
Authors Ali R, Arshad J, Palacio S, Mudad R
Received 25 August 2018
Accepted for publication 9 January 2019
Published 8 February 2019 Volume 2019:13 Pages 569—580
DOI https://doi.org/10.2147/DDDT.S147499
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 3
Editor who approved publication: Professor Manfred Ogris
Robert Ali,1 Junaid Arshad,1 Sofia Palacio,1 Raja Mudad2
1Department of Medicine, Division of Oncology, Jackson Memorial Hospital, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Centre, Miami, FL 33131, USA; 2Department of Medicine, Division of Oncology, University of Miami, Miller School of Medicine, Sylvester Comprehensive Cancer Centre, Miami, FL 33136, USA
Abstract: Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.
Keywords: non-small cell lung cancer, ALK positive, ALK inhibitors, brigatinib, TKI
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.